In: Schaller, A., Alayli, A., Altin, S., Biallas, B., Falkowski, G., Grieben, C., Nitzsche, A., Pfoertner, T. K., Pfaff, H., Stock, S. and Froboese, I. (2016). The bridge between science and practice: Evidence of prevention and health promotion in the context of the structure and objectives of the interdisciplinary research network TRISEARCH. Bewegungstherapie Gesundheitssport, 32 (5). S. 187 - 192. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1613-3269
The social and political expectations towards lifestyle interventions are high. The research association TRISEARCH aims to develop recommendations for evidence development in lifestyle interventions as well as considering the quality perspective of practical partners. In this context, interdisciplinary research and development activities focus on workplace-related interventions that promote health literacy. The present article describes the structure and the aims as well as the content of the research association TRISEARCH.
BACKGROUND: Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) has challenged public health agencies globally. In order to effectively target government responses, it is critical to identify the individuals most at risk of coronavirus disease-19 (COVID-19), developing severe clinical signs, and mortality. We undertook a systematic review of the literature to present the current status of scientific knowledge in these areas and describe the need for unified global approaches, moving forwards, as well as lessons learnt for future pandemics. METHODS: Medline, Embase and Global Health were searched to the end of April 2020, as well as the Web of Science. Search terms were specific to the SARS-CoV-2 virus and COVID-19. Comparative studies of risk factors from any setting, population group and in any language were included. Titles, abstracts and full texts were screened by two reviewers and extracted in duplicate into a standardised form. Data were extracted on risk factors for COVID-19 disease, severe disease, or death and were narratively and descriptively synthesised. RESULTS: One thousand two hundred and thirty-eight papers were identified post-deduplication. Thirty-three met our inclusion criteria, of which 26 were from China. Six assessed the risk of contracting the disease, 20 the risk of having severe disease and ten the risk of dying. Age, gender and co-morbidities were commonly assessed as risk factors. The weight of evidence showed increasing age to be associated with severe disease and mortality, and general comorbidities with mortality. Only seven studies presented multivariable analyses and power was generally limited. A wide range of definitions were used for disease severity. CONCLUSIONS: The volume of literature generated in the short time since the appearance of SARS-CoV-2 has been considerable. Many studies have sought to document the risk factors for COVID-19 disease, disease severity and mortality; age was the only risk factor based on robust studies and with a consistent body of ...
Background: Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) has challenged public health agencies globally. In order to effectively target government responses, it is critical to identify the individuals most at risk of coronavirus disease-19 (COVID-19), developing severe clinical signs, and mortality. We undertook a systematic review of the literature to present the current status of scientific knowledge in these areas and describe the need for unified global approaches, moving forwards, as well as lessons learnt for future pandemics. Methods: Medline, Embase and Global Health were searched to the end of April 2020, as well as the Web of Science. Search terms were specific to the SARS-CoV-2 virus and COVID-19. Comparative studies of risk factors from any setting, population group and in any language were included. Titles, abstracts and full texts were screened by two reviewers and extracted in duplicate into a standardised form. Data were extracted on risk factors for COVID-19 disease, severe disease, or death and were narratively and descriptively synthesised. Results: One thousand two hundred and thirty-eight papers were identified post-deduplication. Thirty-three met our inclusion criteria, of which 26 were from China. Six assessed the risk of contracting the disease, 20 the risk of having severe disease and ten the risk of dying. Age, gender and co-morbidities were commonly assessed as risk factors. The weight of evidence showed increasing age to be associated with severe disease and mortality, and general comorbidities with mortality. Only seven studies presented multivariable analyses and power was generally limited. A wide range of definitions were used for disease severity. Conclusions: The volume of literature generated in the short time since the appearance of SARS-CoV-2 has been considerable. Many studies have sought to document the risk factors for COVID-19 disease, disease severity and mortality; age was the only risk factor based on robust studies and with a consistent body of evidence. Mechanistic studies are required to understand why age is such an important risk factor. At the start of pandemics, large, standardised, studies that use multivariable analyses are urgently needed so that the populations most at risk can be rapidly protected. Registration: This review was registered on PROSPERO as CRD42020177714.
Funding HRS and MF are supported by the Medical Research Council [MR/R008345/1]. CJ's salary came through MRC core funding MC_UU_12023/26. SJS is funded by the Wellcome Trust [WT 209560/Z/17/Z]. CRS has received funding from the Medical Research Council [MR/R008345/1], the National Institute for Health Research [11/46/23] and the New Zealand Health Research Council [20/1018] and Ministry for Business, Innovation and Employment. EV is funded by the Medical Research Council [MR/R008345/1] through the EAVE II grant and supported by the Scottish Government. We also acknowledge the support of HDR UK. The views and opinions expressed here are those of the authors and do not necessarily reflect those of the Health Technology Assessment programme, NIHR, NHS, or the UK Department of Health. Our funders had no role in the design of the study and collection, analysis, and interpretation of data, and in writing the manuscript. ; Peer reviewed ; Publisher PDF
Since the 1980s, research into entomopathogenic nematodes (EPNs) in Latin America has produced many remarkable discoveries. In fact, 16 out of the 117 recognized species of EPNs have been recovered and described in the subcontinent, with many more endemic species and/or strains remaining to be discovered and identified. In addition, from an applied perspective, numerous technological innovations have been accomplished in relation to their implementation in biocontrol. EPNs have been evaluated against over 170 species of agricultural and urban insects, mites, and plant-parasitic nematodes under laboratory and field conditions. While much success has been recorded, many accomplishments remain obscure, due to their publication in non-English journals, thesis dissertations, conference proceedings, and other non-readily available sources. The present review provides a brief history of EPNs in Latin America, including current findings and future perspectives. ; E. San-Blas, M.G. Rodriguez and P. Morales-Montero were supported by Fondo de Desarrollo Nacional (FONDEN S.A.), in the form of financial support through "Convenio de Cooperación Integral Cuba-Venezuela", project "MPPF-FONDEN-CJ-CCATR-XIII-14". R. Campos-Herrera's contribution was supported through an Investigator Program Award (IF/00552/2014) supplied by the Portuguese government. J. Ruiz-Vega thanks the Secretaría de investigación y Posgrado (SIP), Instituto Politécnico Nacional, Mexico for providing resources for the research carried out in Oaxaca from 1998 to 2010.
EAVE II is funded by the Medical Research Council (MC_PC_19075) with the support of BREATHE: the Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and the Community Health and Social Care Directorate of the Scottish Government. R.H. acknowledges support from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford and the NIHR Oxford BREATHE Centre. We thank D. Kelly from Albasoft Limited for support with making primary care data available and J. Pickett, W. Inglis-Humphrey, V. Hammersley, M. Georgiou, L. Brook and L. Gonzalez Rienda for support with project management and administration. We thank the EAVE II Public Advisory Group. Our thanks to J. Quint, R. Al-Shahi Salman and Q. Hill for their help with reviewing code lists. Our thanks also to G. Schiff and L. Smeeth for reviewing this work before submission to the UK's Medicines & Healthcare products Regulatory Agency. Data availability A data dictionary covering the datasets used in this study can be found at https://github.com/ EAVE-II/EAVE-II- data-dictionary. The data that support the findings of this study are not publicly available because they are based on de-identified national clinical records. These are, however, available by application via Scotland's National Safe Haven from Public Health Scotland. The data used in this study can be accessed by researchers through NHS Scotland's Public Benefit and Privacy Panel via its Electronic Data Research and Innovation Service49. Code availability All code used in this study is publicly available at https://github.com/ EAVE-II/Covid- vaccine-safety-haemo. ; Peer reviewed ; Publisher PDF
EAVE II is funded by the Medical Research Council (MC_PC_19075) with the support of BREATHE: the Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and the Community Health and Social Care Directorate of the Scottish Government. R.H. acknowledges support from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford and the NIHR Oxford BREATHE Centre. ; Reports of ChAdOx1 vaccine-associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse events using a nested incident-matched case-control study and a confirmatory self-controlled case series (SCCS) analysis. An association was found between ChAdOx1 vaccination and idiopathic thrombocytopenic purpura (ITP) (0-27 d after vaccination; adjusted rate ratio (aRR) = 5.77, 95% confidence interval (CI), 2.41-13.83), with an estimated incidence of 1.13 (0.62-1.63) cases per 100,000 doses. An SCCS analysis confirmed that this was unlikely due to bias (RR = 1.98 (1.29-3.02)). There was also an increased risk for arterial thromboembolic events (aRR = 1.22, 1.12-1.34) 0-27 d after vaccination, with an SCCS RR of 0.97 (0.93-1.02). For hemorrhagic events 0-27 d after vaccination, the aRR was 1.48 (1.12-1.96), with an SCCS RR of 0.95 (0.82-1.11). A first dose of ChAdOx1 was found to be associated with small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events. The attenuation of effect found in the SCCS analysis means that there is the potential for overestimation of the reported results, which might indicate the presence of some residual confounding or confounding by indication. Public health authorities should inform their jurisdictions of these relatively small increased risks associated with ChAdOx1. No positive associations were seen between BNT162b2 and thrombocytopenic, thromboembolic and hemorrhagic events. ; Publisher PDF ; Peer reviewed
We announce the discovery of two planets orbiting the M dwarfs GJ 251 (0.360 ± 0.015M-) and HD 238090 (0.578 ± 0.021M-) based on CARMENES radial velocity (RV) data. In addition, we independently confirm with CARMENES data the existence of Lalande 21185 b, a planet that has recently been discovered with the SOPHIE spectrograph. All three planets belong to the class of warm or temperate super-Earths and share similar properties. The orbital periods are 14.24 d, 13.67 d, and 12.95 d and the minimum masses are 4.0 ± 0.4 M-, 6.9 ± 0.9 M-, and 2.7 ± 0.3 M- for GJ 251 b, HD 238090 b, and Lalande 21185 b, respectively. Based on the orbital and stellar properties, we estimate equilibrium temperatures of 351.0 ± 1.4 K for GJ 251 b, 469.6 ± 2.6 K for HD 238090 b, and 370.1 ± 6.8 K for Lalande 21185 b. For the latter we resolve the daily aliases that were present in the SOPHIE data and that hindered an unambiguous determination of the orbital period. We find no significant signals in any of our spectral activity indicators at the planetary periods. The RV observations were accompanied by contemporaneous photometric observations. We derive stellar rotation periods of 122.1 ± 2.2 d and 96.7 ± 3.7 d for GJ 251 and HD 238090, respectively. The RV data of all three stars exhibit significant signals at the rotational period or its first harmonic. For GJ 251 and Lalande 21185, we also find long-period signals around 600 d, and 2900 d, respectively, which we tentatively attribute to long-term magnetic cycles. We apply a Bayesian approach to carefully model the Keplerian signals simultaneously with the stellar activity using Gaussian process regression models and extensively search for additional significant planetary signals hidden behind the stellar activity. Current planet formation theories suggest that the three systems represent a common architecture, consistent with formation following the core accretion paradigm. ; With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (MDM-2017-0737)
Context. The nearby ultra-compact multiplanetary system YZ Ceti consists of at least three planets, and a fourth tentative signal. The orbital period of each planet is the subject of discussion in the literature due to strong aliasing in the radial velocity data. The stellar activity of this M dwarf also hampers significantly the derivation of the planetary parameters. Aims. With an additional 229 radial velocity measurements obtained since the discovery publication, we reanalyze the YZ Ceti system and resolve the alias issues. Methods. We use model comparison in the framework of Bayesian statistics and periodogram simulations based on a method by Dawson and Fabrycky to resolve the aliases. We discuss additional signals in the RV data, and derive the planetary parameters by simultaneously modeling the stellar activity with a Gaussian process regression model. To constrain the planetary parameters further we apply a stability analysis on our ensemble of Keplerian fits. Results. We find no evidence for a fourth possible companion. We resolve the aliases: the three planets orbit the star with periods of 2.02 d, 3.06 d, and 4.66 d. We also investigate an effect of the stellar rotational signal on the derivation of the planetary parameters, in particular the eccentricity of the innermost planet. Using photometry we determine the stellar rotational period to be close to 68 d and we also detect this signal in the residuals of a three-planet fit to the RV data and the spectral activity indicators. From our stability analysis we derive a lower limit on the inclination of the system with the assumption of coplanar orbits which is i(min) = 0.9 deg. From the absence of a transit event with TESS, we derive an upper limit of the inclination of i(max) = 87.43 deg. Conclusions. YZ Ceti is a prime example of a system where strong aliasing hindered the determination of the orbital periods of exoplanets. Additionally, stellar activity influences the derivation of planetary parameters and modeling them correctly is important for the reliable estimation of the orbital parameters in this specific compact system. Stability considerations then allow additional constraints to be placed on the planetary parameters. ; German Research Foundation (DFG) FOR2544 RE 2694/4-1 German Max-Planck-Gesellschaft (MPG) Consejo Superior de Investigaciones Cientificas (CSIC) European Union through FEDER/ERF FICTS -2011 -02 Spanish Ministry of Economy German Science Foundation through the Major Research Instrumentation Programme Klaus Tschira Stiftung state of Baden-Wurttemberg state of Niedersachsen Junta de Andalucia High Performance and Cloud Computing Group at the Zentrum fur Datenverarbeitung of the University of Tubingen state of Baden-Wurttemberg through bwHPC German Research Foundation (DFG) INST 37/935 -1 FUGG European FEDER/ERF funds AYA2015-69350-C3-2-P AYA2016-79425-C3-1/2/3-P ESP2017-87676-C5-2-R ESP2017-87143-R Centre of Excellence "Severo Ochoa" award SEV-2015-0548 Centre of Excellence "Maria de Maeztu" award SEV-2015-0548 Instituto de Astrofisica de Andalucia SEV-2017-0709 Centro de Astrobiologia MDM-2017-0737 Generalitat de Catalunya/CERCA programme Science & Technology Facilities Council (STFC) ST/M001008/1 ST/P000584/1 Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT 1161218 Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) PB06 Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT 3180405 Hong Kong RGC grant HKU 17305618 European Research Council under the Horizon 2020 Framework Program via the ERC 83 24 28 Max-Planck-Institut fur Astronomie Instituto de Astrofisica de Andalucia Landessternwarte Konigstuhl Institut de Ciencies de l'Espai Insitut fur Astrophysik Gottingen Universidad Complutense de Madrid Thuringer Landessternwarte Tautenburg Instituto de Astrofisica de Canarias Hamburger Sternwarte Centro de Astrobiologia Centro Astronomico Hispano -Aleman Agencia Estatal de Investigacion of the Ministerio de Ciencia, Innovacion y Universidades AYA2015-69350-C3-2-P AYA2016-79425-C3-1/2/3-P ESP2017-87676-C5-2-R ESP2017-87143-R